analyst
KR
NASDAQ · KRYS
Krystal Biotech, Inc.
Healthcare · Biotechnology
$336.68
Down-$3.35 (-0.99%)
Updated Sep 16, 2026, 7:53 AM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.16B
- P/E ratio
- 35.94
- Dividend yield
- 0.00%
- 52-week range
- $155.20 – $382.54
- Volume
- 225.82K
- Avg. volume
- 324.53K
Price performance
KRYS price history
1M range · 20 trading sessions · Daily adjusted prices
KRYS closed at $336.68 after 20 trading sessions, up 1.16% for the selected period.
- Last close
- $336.68
- Period change
- +1.16%
- Period low
- $332.82
- Period high
- $371.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $339.01 | $340.0899 | $331.7948 | $336.68 | 225.82K |
| Sep 14, 2026 | $349.14 | $352.545 | $339.25 | $340.03 | 288.54K |
| Sep 11, 2026 | $349.59 | $354.2404 | $346.68 | $347.00 | 206.32K |
| Sep 10, 2026 | $347.56 | $349.655 | $344.26 | $345.55 | 175.79K |
| Sep 9, 2026 | $348.85 | $353.115 | $340.175 | $348.09 | 222.38K |
| Sep 8, 2026 | $350.49 | $354.6877 | $343.46 | $351.26 | 255.88K |
| Sep 4, 2026 | $365.45 | $371.99 | $353.745 | $358.24 | 323.02K |
| Sep 3, 2026 | $371.41 | $373.31 | $365.555 | $371.47 | 226.49K |
| Sep 2, 2026 | $366.00 | $373.19 | $360.86 | $369.23 | 305.2K |
| Sep 1, 2026 | $360.00 | $364.44 | $358.38 | $363.84 | 197.43K |
| Aug 31, 2026 | $348.62 | $363.52 | $345.14 | $359.36 | 222.78K |
| Aug 28, 2026 | $356.92 | $356.92 | $348.57 | $351.46 | 143.51K |
| Aug 27, 2026 | $357.61 | $362.50 | $355.09 | $357.46 | 181.43K |
| Aug 26, 2026 | $354.37 | $363.82 | $350.43 | $359.76 | 281.03K |
| Aug 25, 2026 | $343.81 | $357.91 | $343.81 | $356.19 | 205.05K |
| Aug 24, 2026 | $343.51 | $346.5499 | $337.09 | $341.72 | 236.71K |
| Aug 21, 2026 | $337.44 | $348.03 | $335.72 | $346.58 | 407.81K |
| Aug 20, 2026 | $338.32 | $343.14 | $334.99 | $337.02 | 196.7K |
| Aug 19, 2026 | $339.61 | $345.5599 | $335.44 | $343.34 | 162.84K |
| Aug 18, 2026 | $332.18 | $337.405 | $330.31 | $332.82 | 148.47K |
Latest KRYS news
The latest Smart Investors Daily articles mentioning KRYS.
Stock researchCompany · Overview
KRYS research
Overview
Company profile and research snapshot.
Company profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $220.00
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
| Jul 14, 2026 | B of A Securities | Buy | — |
| Jun 18, 2026 | TD Cowen | Buy | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.